Dermatology Efficacy

Results at week 12

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz is the first and only FDA-approved IL-17A antagonist that includes PASI 100 in the Prescribing Information¹

In UNCOVER-2, 83% of patients taking Taltz achieved sPGA 0,1 vs 2% who received placebo.

ADDITIONAL WEEK 12 RESULTS

In UNCOVER-1 (Taltz n=433; placebo n=431) and UNCOVER-3 (Taltz n=385; placebo n=193), Taltz patients achieved similar results: 89% and 87% of Taltz patients achieved PASI 75 vs 4% and 7% for placebo. Additionally, 71% and 68% of Taltz patients achieved PASI 90 vs 1% and 3% for placebo, and 35% and 38% of Taltz patients achieved PASI 100 vs 0% and 0% for placebo. Also, 82% and 81% of Taltz patients achieved sPGA 0,1 vs 3% and 7% for placebo.

Trial design

SELECT IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

: FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz works early and effectively by week 12²

Trial design

SELECT IMPORTANT SAFETY INFORMATION
INFECTIONS
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

: FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz provided high levels of efficacy compared to placebo at week 12 regardless of previous treatment with a biologic^1,3

In these trials, 83% of biologic-naive and 80% of biologic-experienced patients receiving Taltz achieved sPGA 0,1 vs 5% and 2%, respectively, for patients receiving placebo.

In the placebo group, biologic-naive (n=535) and biologic-experienced (n=257) patients achieved PASI 75 rates of 5% and 3%, PASI 90 rates of 2% and 0%, and PASI 100 rates of 0% and 0%, respectively.

Trial design

SELECT IMPORTANT SAFETY INFORMATION
PRE-TREATMENT EVALUATION FOR TUBERCULOSIS
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Efficacy you can see

: FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

See the difference Taltz can make in 12 weeks^4-7

Copying, downloading, or other use of patient photos is expressly prohibited.

Psoriasis can impact all areas of the body. The following images are of real adult patients with moderate to severe psoriasis who were treated with Taltz over a 12-week period. Photos at baseline and week 12 can be viewed below. Individual results may vary.

PASI 75

PATIENT AT BASELINE
(PASI SCORE=19.2)

PATIENT AT WEEK 12
(PASI SCORE=2.8)

Patients received a 160 mg starting dose of Taltz; then 80 mg of Taltz every 2 weeks.

Trial design

SELECT IMPORTANT SAFETY INFORMATION
HYPERSENSITIVITY
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

: FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

See the difference Taltz can make in 12 weeks^4-7

Copying, downloading, or other use of patient photos is expressly prohibited.

Psoriasis can impact all areas of the body. The following images are of real adult patients with moderate to severe psoriasis who were treated with Taltz over a 12-week period. Photos at baseline and week 12 can be viewed below. Individual results may vary.

PASI 90

PATIENT AT BASELINE
(PASI SCORE=32.5)

PATIENT AT WEEK 12
(PASI SCORE=2.3)

Patients received a 160 mg starting dose of Taltz; then 80 mg of Taltz every 2 weeks.

Trial design

SELECT IMPORTANT SAFETY INFORMATION
INFLAMMATORY BOWEL DISEASE
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbation of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

: FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

See the difference Taltz can make in 12 weeks^4-7

Copying, downloading, or other use of patient photos is expressly prohibited.

Psoriasis can impact all areas of the body. The following images are of real adult patients with moderate to severe psoriasis who were treated with Taltz over a 12-week period. Photos at baseline and week 12 can be viewed below. Individual results may vary.

PASI 100

PATIENT AT BASELINE
(PASI SCORE=13)

PATIENT AT WEEK 12
(PASI SCORE=0)

Patients received a 160 mg starting dose of Taltz; then 80 mg of Taltz every 2 weeks.

Trial design

SELECT IMPORTANT SAFETY INFORMATION
IMMUNIZATIONS
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

: FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

See the difference Taltz can make in 12 weeks^4-7

Copying, downloading, or other use of patient photos is expressly prohibited.

Psoriasis can impact all areas of the body. The following images are of real adult patients with moderate to severe psoriasis who were treated with Taltz over a 12-week period. Photos at baseline and week 12 can be viewed below. Individual results may vary.

PASI sPGA 0,1

PATIENT AT BASELINE
(PASI SCORE=4)

PATIENT AT WEEK 12
(PASI SCORE=1)

Patients received a 160 mg starting dose of Taltz; then 80 mg of Taltz every 2 weeks.

Trial design

SELECT IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis, and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

Week 60 results

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Reassure your patients that consistent results can be maintained with Taltz at week 60¹

Trial design

SELECT IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Week 264 results

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Consistent range of response through 5 years, mNRI and observed⁹

Induction period and open-label extension

^*Nx=observed population.

A subset of patients from UNCOVER-3 who received a 160 mg starting dose of Taltz at week 0, followed by 80 mg every 2 weeks through week 12, followed by 80 mg every 4 weeks, is shown.

The open-label phase of the study beginning after week 12 has limitations (e.g., no placebo comparison, patients remaining in the extension phase may be those with better results).

In an mNRI analysis of patients receiving Taltz at week 60, 89% of patients achieved PASI 75, 78% of patients achieved PASI 90, and 59% of patients achieved PASI 100. In an mNRI analysis of patients receiving Taltz at weeks 108, 156, 204, and 264, 84%, 82%, 83%, and 79% of patients, respectively, achieved PASI 75; 71%, 69%, 66%, and 67% of patients, respectively, achieved PASI 90; and 50%, 49%, 48%, and 46% of patients, respectively, achieved PASI 100.

mNRI of intent-to-treat population through week 264.

mNRI analysis imputes missing data due to study drug (eg, inadequate response, adverse event, lack of efficacy) as nonresponse; whereas missing data due to other reasons (eg, missed visits, lost to follow-up) is included as a predicted value based on statistical modeling of observed data.

mNRI=modified nonresponder imputation.

Trial design

SELECT IMPORTANT SAFETY INFORMATION
INFECTIONS
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Rapid clearance by week 12 that was sustained through week 264¹⁰

UNCOVER-3 mean PASI scores through week 264 observed

Post hoc observed analyses of ITT population through week 264.

In UNCOVER-1, patients receiving Taltz achieved a mean PASI of 1.9 (an 88% improvement from the mean baseline score of 20.1) at week 12. Patients receiving placebo achieved a mean PASI of 18.9 (a 3% improvement from the mean baseline score of 20.3) at week 12.

In UNCOVER-2, patients receiving Taltz achieved a mean PASI of 1.7 (a 91% improvement from the mean baseline score of 19.4) at week 12. Patients receiving placebo achieved a mean PASI of 19.1 (a 7% improvement from the mean baseline score of 20.6) at week 12.

A subset of patients from UNCOVER-3 who received a 160 mg starting dose of Taltz at week 0, followed by 80 mg every 2 weeks through week 12, followed by 80 mg every 4 weeks, is shown. Patients and site personnel were blinded to study treatment until all patients completed week 12 or discontinued. The open-label extension phase of the study has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).

SELECT IMPORTANT SAFETY INFORMATION
PRE-TREATMENT EVALUATION FOR TUBERCULOSIS
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Trust Taltz to offer

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Achieves complete resolution of plaques (PASI 100) and has data through 264 weeks^11-17

Click here for data

Early, visible results by week 12²

Click here for data

Data in challenging body areas^11-17

Click here for data

Trial design

SELECT IMPORTANT SAFETY INFORMATION
HYPERSENSITIVITY
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

References: 1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020. 2. Data on file. Lilly USA, LLC. TAL20160223C. 3. Data on file. Lilly, USA, LLC. TAL20160328C. 4. Data on File. Lilly USA, LLC. TAL20160222D. 5. Data on File. Lilly USA, LLC. TAL20160222A. 6. Data on File. Lilly USA, LLC. TAL20160222E. 7. Data on File. Lilly USA, LLC. TAL20160222B. 8. Data on file. Lilly USA, LLC. DOF-IX-US-0274. 9. Data on file. Lilly USA, LLC. DOF-IX-US-0197. 10. Data on file. Lilly USA, LLC. DOF-IX-US-0232. 11. Data on file. Lilly USA, LLC DOF-IX-US-0237. 12. Blauvelt A, Lebwohl MG, Mabuchi T, Leung A, Garrelts A, Crane H, ElMaraghy H, Patel H, Ridenour T, See K, Gallo G, Paul C. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2020 Nov 28:S0190-9622(20)33053-X. doi: 10.1016/j.jaad.2020.11.022. Epub ahead of print. PMID: 33253833. 13. Data on file. Lilly USA, LLC. DOF-IX-US-0271. 14. Data on file. Lilly USA, LLC. DOF-IX-US-0259. 15. Data on file. Lilly USA, LLC. DOF-IX-US-0258. 16. Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A; IXORA-Q Study Group. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018 Oct;179(4):844-852. doi: 10.1111/bjd.16736. Epub 2018 Jul 22. PMID: 29747232. 17. Data on file. Lilly USA, LLC. DOF-IX-US-0263.

Dermatology Efficacy

Results at week 12

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz is the first and only FDA-approved IL-17A antagonist that includes PASI 100 in the Prescribing Information1

ADDITIONAL WEEK 12 RESULTS

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz works early and effectively by week 122

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz provided high levels of efficacy compared to placebo at week 12 regardless of previous treatment with a biologic1,3

Efficacy you can see

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

See the difference Taltz can make in 12 weeks4-7

PASI 75

PATIENT AT BASELINE(PASI SCORE=19.2)

PATIENT AT WEEK 12(PASI SCORE=2.8)

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

See the difference Taltz can make in 12 weeks4-7

PASI 90

PATIENT AT BASELINE(PASI SCORE=32.5)

PATIENT AT WEEK 12(PASI SCORE=2.3)

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

See the difference Taltz can make in 12 weeks4-7

PASI 100

PATIENT AT BASELINE(PASI SCORE=13)

PATIENT AT WEEK 12(PASI SCORE=0)

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

See the difference Taltz can make in 12 weeks4-7

PASI sPGA 0,1

PATIENT AT BASELINE(PASI SCORE=4)

PATIENT AT WEEK 12(PASI SCORE=1)

Week 60 results

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Reassure your patients that consistent results can be maintained with Taltz at week 601

Week 264 results

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Consistent range of response through 5 years, mNRI and observed9

Induction period and open-label extension

Rapid clearance by week 12 that was sustained through week 26410

Trust Taltz to offer

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Achieves complete resolution of plaques (PASI 100) and has data through 264 weeks11-17

Early, visible results by week 122

Data in challenging body areas11-17

Taltz is the first and only FDA-approved IL-17A antagonist that includes PASI 100 in the Prescribing Information¹

Taltz works early and effectively by week 12²

Taltz provided high levels of efficacy compared to placebo at week 12 regardless of previous treatment with a biologic^1,3

See the difference Taltz can make in 12 weeks^4-7

PATIENT AT BASELINE
(PASI SCORE=19.2)

PATIENT AT WEEK 12
(PASI SCORE=2.8)

See the difference Taltz can make in 12 weeks^4-7

PATIENT AT BASELINE
(PASI SCORE=32.5)

PATIENT AT WEEK 12
(PASI SCORE=2.3)

See the difference Taltz can make in 12 weeks^4-7

PATIENT AT BASELINE
(PASI SCORE=13)

PATIENT AT WEEK 12
(PASI SCORE=0)

See the difference Taltz can make in 12 weeks^4-7

PATIENT AT BASELINE
(PASI SCORE=4)

PATIENT AT WEEK 12
(PASI SCORE=1)

Reassure your patients that consistent results can be maintained with Taltz at week 60¹

Consistent range of response through 5 years, mNRI and observed⁹

Rapid clearance by week 12 that was sustained through week 264¹⁰

Achieves complete resolution of plaques (PASI 100) and has data through 264 weeks^11-17

Early, visible results by week 12²

Data in challenging body areas^11-17